Akseera’s goal is to provide patients with safe Cannabinoid pharmaceutical formulations in order to meet the stringent requirements of health authorities such as Health Canada and the United States Food and Drug Administration (USFDA). Akseera is researching and developing cannabinoid-based products for the prescription drug market and is working toward developing cannabinoid based pharmaceutical formulations for the treatment of COVID -19, Arrythmias, prostate cancer, neurological disorders and other rare and difficult to manage conditions.
Akseera’s Cannabinoids Production Strategy
Akseera is invested in the development of processes to produce Cannabinoid isolates in the lab as a cost-effective solutions to improve production efficiency, therapeutic efficacy and product quality.
Our lab-based synthesis project is directed towards addressing challenges associated with production of isolates from the Cannabis plant:
- overcoming seasonal variations
- obtaining contaminant-free isolates
- higher yields of minor cannabinoids
- purity to meet pharmaceutical standards
We are pursuing Organic Synthesis of Cannabinoids to produce high quality and consistent to meet requirements mandated for Pharmaceutical applications. Based on the principles of chemical synthesis, our proprietary process is designed to optimize production efficiency and reducing cost of these compounds. Prototypes are anticipated by Summer 2020.
Akseera’s Biosynthesis project is geared towards producing Cannabinoids in the lab through genetic engineering such that it meets regulatory standards for pharmaceutical applications, ensure consistent production and can be classified as natural.
The process of biosynthesis entails genetic engineering of microorganisms to produce heterologous chemicals. The technology has been used for decades for the production of numerous chemicals such as active pharmaceutical and food ingredients, monoclonal antibodies, intermediates to name a few. The safety of biosynthetic products is established as several vitamins, antibiotics, beverages are biosynthetic products.
Our approach to lab-based Cannabinoids, stands distinct from our competitors, in that can be translated into large scale production, while meeting quality standards set for the Pharma, Food, Beverage, and legal recreational industries while making the products scalable and cost effective.
Augmenting COVID-19 Therapies
The COVID-19 Pandemic has accounted for millions of infections worldwide and claimed hundreds of thousands of lives in just a few months. The number of infections continue to rise at unprecedented rates. With no proven vaccine or cure available, isolation and social distancing are currently the only effective control measures. Akseera is currently working on research with Cannabidiol (CBD) which can potentially mitigate side effects of candidate medications in clinical trials. Our project presents an opportunity to leverage the scientific expertise in Canada and its pioneer position in the cannabis industry to mitigate global health challenges.